Examining Strategies to Increase Lung Cancer Screenings Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(17):15-16, September 5, 2023. Favorite PDF Permissions Free
Osimertinib Improves Survival in Resected EGFR-Mutated NSCLC Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(15):22, August 5, 2023. Favorite PDF Permissions Free
Novel Technology for Semi-Solid Lung & Immuno-Resistant Tumors Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(15):17-18, August 5, 2023. Favorite PDF Permissions Free
Anti-Aging Effects of Rapalogs Extend Lifespan, Decrease Tumor Burden Wiley, Frieda Wiley, Frieda Less Oncology Times. 45(15):14, August 5, 2023. Favorite PDF Permissions Free
Study Validates Stopping Immune Therapy for NSCLC at 2 Years Holt, Chuck Holt, Chuck Less Oncology Times. 45(15):7, August 5, 2023. Favorite PDF Permissions Free
Tremelimumab-Actl (Imjudo™) Haarberg, Sasha Haarberg, Sasha Less Oncology Times. 45(14):11, July 20, 2023. Favorite PDF Permissions Free
Severe Myelosuppression Following Small Cell Lung Cancer Chemotherapy Nolen, Lindsey Nolen, Lindsey Less Oncology Times. 45(14):1,10,25, July 20, 2023. Favorite PDF Permissions Free
Outcomes in U.S. Veterans Treated for Non-Small Cell Lung Cancer Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(13):15, July 5, 2023. Favorite PDF Permissions Free
A Closer Look at Personalized Cancer Screening & Recommendations Jenks, Susan Jenks, Susan Less Oncology Times. 45(13):13,25, July 5, 2023. Favorite PDF Permissions Free
Social Determinants of Health in Patients With Mesothelioma Galamba, Elizabeth Rose Galamba, Elizabeth Rose Less Oncology Times. 45(13):1,4, July 5, 2023. Favorite PDF Permissions Free
Updated Findings of the Phase II LCMC3 Trial of Lung Cancer Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(12):21, June 20, 2023. Favorite PDF Permissions Free
Cemiplimab + Chemo Shows Clinical Benefit in Advanced NSCLC Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(12):20, June 20, 2023. Favorite PDF Permissions Free
Perioperative Toripalimab + Chemo in Stage III Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(11):6, June 5, 2023. Favorite PDF Permissions Free
Research Data Examines Inflammatory Depression in Lung Cancer DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 45(10):31, May 20, 2023. Favorite PDF Permissions Free
Partnering With Community Health Centers to Decrease Tobacco Use Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(4):16-17, February 20, 2023. Favorite PDF Permissions Free
FDA Accelerated Approval of Adagrasib for Non-Small Cell Lung Cancer Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(4):1,9, February 20, 2023. Favorite PDF Permissions Free
Novel Antibody Adds Benefit to Immunotherapy in Advanced Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(3):19, February 5, 2023. Favorite PDF Permissions Free
The Impact of Tumor-Infiltrating B Cells in Lung Adenocarcinoma Nolen, Lindsey Nolen, Lindsey Less Oncology Times. 45(2):10-11, January 20, 2023. Favorite PDF Permissions Free CME Test
Adagrasib (Krazati™) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 45(2):8,15, January 20, 2023. Favorite PDF Permissions Free
The Importance of Early Screening in Improving Lung Cancer Survival Rates McGraw, Mark McGraw, Mark Less Oncology Times. 45(1):32, January 5, 2023. Favorite PDF Permissions Free
ROS1 Inhibitor Brings Responses in Refractory Solid Tumors Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 45(1):30, January 5, 2023. Favorite PDF Permissions Free
Next-Generation ROS1 Inhibitor Brings High Response Rates in Lung Cancer Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 45(1):29, January 5, 2023. Favorite PDF Permissions Free
The Role of Asbestos in Global Malignant Mesothelioma Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(1):24, January 5, 2023. Favorite PDF Permissions Free
Medical Mistrust Among Patients & the Impact on Lung Cancer Screening Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(23):26, December 5, 2022. Favorite PDF Permissions Free
Overall Survival Trend Spotted in Adjuvant Therapy for NSCLC Holt, Chuck Holt, Chuck Less Oncology Times. 44(22):32,34, November 20, 2022. Favorite PDF Permissions Free
Pembrolizumab With Etoposide/Platinum for First-Line Small Cell Lung Cancer Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(22):20-21, November 20, 2022. Favorite PDF Permissions Free CME Test
Breaking Down Disparity Barriers in Lung Cancer Screening Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(21):1,9, November 5, 2022. Favorite PDF Permissions Free
Deep Learning Algorithm Could Make Lung Cancer Radiotherapy More Efficient McGraw, Mark McGraw, Mark Less Oncology Times. 44(20):20, October 20, 2022. Favorite PDF Permissions Free
NSCLC Patients With High Levels of MET Overexpression/Amplification Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(20):12, October 20, 2022. Favorite PDF Permissions Free
Pembrolizumab With or Without Chemotherapy for NSCLC Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(19):23, October 5, 2022. Favorite PDF Permissions Free
Neoadjuvant vs. Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(19):22, October 5, 2022. Favorite PDF Permissions Free
Exploring New Platforms to Fight Small Cell Lung Cancer Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(19):17-18, October 5, 2022. Favorite PDF Permissions Free
Unfit Patients With Lung Cancer Lived Longer With First-Line Immunotherapy Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 44(19):14, October 5, 2022. Favorite PDF Permissions Free
All Lung Cancer Patients Should Have Germline Testing for Mutations Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(18):19, September 20, 2022. Favorite PDF Permissions Free
NELSON Lung Screening Protocol More Sensitive Than NLST in Detecting Cancer McGraw, Mark McGraw, Mark Less Oncology Times. 44(18):15, September 20, 2022. Favorite PDF Permissions Free
Novel Diagnostic Platform Predicts NSCLC Patient Response to Immunotherapy Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(17):17-18, September 5, 2022. Favorite PDF Permissions Free
Better Treatment Options & Answers to Therapy Resistance in Lung Cancer Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(17):1,9-10, September 5, 2022. Favorite PDF Permissions Free
The Use of Liquid Biopsies & Tissue Biopsies for Lung Cancer Less Oncology Times. 44(16):8, August 20, 2022. Favorite PDF Permissions Free
3 QUESTIONS ON... Improved Early Detection in Lung Cancer: With Raymond U. Osarogiagbon, MBBS, FACP, at Baptist Memorial Health Care DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 44(15):34, August 5, 2022. Favorite PDF Permissions Free
Finding a Cytoskeletal Signature of Partial EMT Phenotype in Lung Cancer Holt, Chuck Holt, Chuck Less Oncology Times. 44(15):5,8, August 5, 2022. Favorite PDF Permissions Free
AI-Based Tool Aids Cancer Risk Prediction of Lung Nodules McGraw, Mark McGraw, Mark Less Oncology Times. 44(15):1,8, August 5, 2022. Favorite PDF Permissions Free
ART1 As a Targetable Regulator of Immune Resistance in NSCLC Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(13):28,33, July 5, 2022. Favorite PDF Permissions Free
Lung Cancer Brain Metastases Respond to Anti-KRAS Therapy With Adagrasib Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 44(13):21, July 5, 2022. Favorite PDF Permissions Free
Targeting KEAP1-Mutant NSCLC With Broad-Acting Glutamine Antagonist Papagiannakopoulos, Thales Papagiannakopoulos, Thales Less Oncology Times. 44(13):1,12, July 5, 2022. Favorite PDF Permissions Free
3 QUESTIONS ON... Helping Cancer Patients Stop Smoking: With Luke Shenton, MPH, & Ann Klassen, PhD, of Drexel University College of Medicine DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 44(10):38, May 20, 2022. Favorite PDF Permissions Free
Circulating Tumor DNA Assay Predicts Lung Cancer Relapse Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 44(10):32, May 20, 2022. Favorite PDF Permissions Free
Research Finds MRI Can Noninvasively Assess Smoking, Vaping Effects McGraw, Mark McGraw, Mark Less Oncology Times. 44(10):30, May 20, 2022. Favorite PDF Permissions Free
Nivolumab & Chemo Combination as Standard of Care for NSCLC Froelich, Warren Froelich, Warren Less Oncology Times. 44(10):29,33, May 20, 2022. Favorite PDF Permissions Free
Quantifying Minimal Residual Disease in Patients With Small Cell Lung Cancer Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(9):28, May 5, 2022. Favorite PDF Permissions Free
Modifications to Lung Cancer Screening During COVID-19 Pandemic Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(9):27, May 5, 2022. Favorite PDF Permissions Free
LDCT & Lung Nodule Screening Combine to Detect More Cancer McGraw, Mark McGraw, Mark Less Oncology Times. 44(9):11, May 5, 2022. Favorite PDF Permissions Free
Tuberculosis in Cancer Treated With Immune Checkpoint Inhibitors Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(8):35, April 20, 2022. Favorite PDF Permissions Free
Addition of Toripalimab to First-Line Chemo Improves NSCLC Survival Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(8):34, April 20, 2022. Favorite PDF Permissions Free
Lung-RADS Helpful, But Should Be Periodically Reassessed McGraw, Mark McGraw, Mark Less Oncology Times. 44(6):29, March 20, 2022. Favorite PDF Permissions Free
Radiation Therapy in Oligoprogressive NSCLC & Breast Cancer Holt, Chuck Holt, Chuck Less Oncology Times. 44(3):17,24, February 5, 2022. Favorite PDF Permissions Free
Integrating Precision Oncology in Lung Cancer Discovery & Management Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(3):1,19-20, February 5, 2022. Favorite PDF Permissions Free
Promising Therapeutic Strategy in Malignant Pleural Mesothelioma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(2):20,31, January 20, 2022. Favorite PDF Permissions Free
Mobocertinib (Exkivity™) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 44(2):11-12, January 20, 2022. Favorite PDF Permissions Free
The Role of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer Kazmi, Shayma Master Kazmi, Shayma Master Less Oncology Times. 44(2):1,7, January 20, 2022. Favorite PDF Permissions Free
Spotlight: Understanding Lung Cancer in Never-Smokers Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(1):1,16, January 5, 2022. Favorite PDF Permissions Free
Researchers Explore Multiomics Data From Early-Stage NSCLC Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(24):29, December 20, 2021. Favorite PDF Permissions Free
3 QUESTIONS ON... What Drives Lung Cancer in Never-Smokers: With Siddhartha Devarakonda, MD, of Washington University School of Medicine DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 43(22):34, November 20, 2021. Favorite PDF Permissions Free
First-Line Cemiplimab + Chemo Improves Outcomes in Advanced NSCLC Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(22):23, November 20, 2021. Favorite PDF Permissions Free
Durvalumab + Tremelimumab Improves Survival in Metastatic NSCLC Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(19):34, October 5, 2021. Favorite PDF Permissions Free
The Promise of CAR T-Cell Therapy in Mesothelioma Treatment Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(19):24, October 5, 2021. Favorite PDF Permissions Free
Year In Review: 2021 Mesothelioma Treatments & Clinical Trials Less Oncology Times. 43(19):20, October 5, 2021. Favorite PDF Permissions Free
Novel AI Blood Testing Technology Can ID Lung Cancers With High Accuracy Less Oncology Times. 43(18):33, September 20, 2021. Favorite PDF Permissions Free
A Model to Predict NSCLC Patient Outcomes to Immunotherapy Less Oncology Times. 43(18):24, September 20, 2021. Favorite PDF Permissions Free
New Hope for NSCLC Patients With EGFR Exon 20 Insertion Mutations Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(18):13, September 20, 2021. Favorite PDF Permissions Free
A More Complete Molecular Picture of Lung Squamous Cell Carcinoma Less Oncology Times. 43(17):32,38, September 5, 2021. Favorite PDF Permissions Free
MET Amplification as Driver for Some Non-Small Cell Lung Cancers Less Oncology Times. 43(16):24, August 20, 2021. Favorite PDF Permissions Free
Sotorasib (Lumakras™) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 43(15):12,17, August 5, 2021. Favorite PDF Permissions Free
BMI May Not Be Best Obesity Indicator to Assess Risk for Lung Cancer Less Oncology Times. 43(14):14, July 20, 2021. Favorite PDF Permissions Free
Risks of Recurrence & Death When Delaying Lung Cancer Surgery Less Oncology Times. 43(12):28, June 20, 2021. Favorite PDF Permissions Free
Missing Protein in SCLC May Explain Poor Response to Immunotherapies DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 43(12):25, June 20, 2021. Favorite PDF Permissions Free
Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC Cascone, Tina Cascone, Tina Less Oncology Times. 43(12):1,11, June 20, 2021. Favorite PDF Permissions Free
Predicting Lung Cancer Risk in Diverse Populations Less Oncology Times. 43(11):44, June 5, 2021. Favorite PDF Permissions Free
A Biomarker That May Predict NSCLC Response to Immunotherapy DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 43(10):38, May 20, 2021. Favorite PDF Permissions Free
Overcoming Challenges to Broaden Adoptive T-Cell Therapy in Lung Cancer Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 43(9):19-20, May 5, 2021. Favorite PDF Permissions Free
USPSTF Updates Lung Cancer Screening Guidelines DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 43(9):1,11, May 5, 2021. Favorite PDF Permissions Free
A Metabolic Pathway Driving Growth of Aggressive Lung Cancers Gallagher, Amy Gallagher, Amy Less Oncology Times. 43(8):29, April 20, 2021. Favorite PDF Permissions Free
Antimalarial Atovaquone May Improve Lung Cancer Treatment Outcomes Balakrishnan, Vijay Shankar Balakrishnan, Vijay Shankar Less Oncology Times. 43(8):27, April 20, 2021. Favorite PDF Permissions Free
Lung Cancer Patients at Risk of Hyperprogressive Disease Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(8):23,25, April 20, 2021. Favorite PDF Permissions Free
Deep Learning Models Tackle Lung Cancer Survival Period Prediction Holt, Chuck Holt, Chuck Less Oncology Times. 43(8):21, April 20, 2021. Favorite PDF Permissions Free
The Impact of the COVID-19 Pandemic on Lung Cancer Screening Nolen, Lindsey Nolen, Lindsey Less Oncology Times. 43(8):12, April 20, 2021. Favorite PDF Permissions Free
3 QUESTIONS ON... When Enthusiasm for New Cancer Drugs Is Premature: With Bishal Gyawali, MD, PhD, of Queen's University Cancer Research Institute, Kingston, Ontario, Canada DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 43(7):42, April 5, 2021. Favorite PDF Permissions Free
Capmatinib (Tabrecta™) Sproat, Michelle; Mann, Janelle E. Sproat, Michelle; Mann, Janelle E. Less Oncology Times. 43(6):14,41, March 20, 2021. Favorite PDF Permissions Free
Predicting Recurrence in Patients With Completely Resected Lung Cancer Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(5):17, March 5, 2021. Favorite PDF Permissions Free
Artificial Intelligence Facilitates Accurate NSCLC Treatment Decisions Samson, Kurt Samson, Kurt Less Oncology Times. 43(4):34, February 20, 2021. Favorite PDF Permissions Free
Tackling Muscle Wasting & Malnutrition Among Lung Cancer Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(3):16-17, February 5, 2021. Favorite PDF Permissions Free
Cemiplimab Monotherapy as First-Line Treatment for Certain NSCLC Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(1):34, January 5, 2021. Favorite PDF Permissions Free
Predicting the Risk of Severe Side Effects of Cancer Treatment Less Oncology Times. 42(24):71, December 20, 2020. Favorite PDF Permissions Free
FDA Approval of Immunotherapy Drugs Brings Hope to Mesothelioma Patients Conick, Hal Conick, Hal Less Oncology Times. 42(24):1,5, December 20, 2020. Favorite PDF Permissions Free
Ensartinib as Treatment for ALK-Rearranged NSCLC Wong, Selina K.; Cass, Amanda S.; Horn, Leora Wong, Selina K.; Cass, Amanda S.; Horn, Leora Less Oncology Times. 42(20):1-8, October 20, 2020. Favorite PDF Permissions Free
Ensartinib as Treatment for ALK-Rearranged NSCLC Wong, Selina K.; Cass, Amanda S.; Horn, Leora Wong, Selina K.; Cass, Amanda S.; Horn, Leora Less Oncology Times. 42(20):1-8, October 20, 2020. Favorite PDF Permissions Free
RET Inhibitor Selpercatinib Achieves Durable Responses in Lung Cancer Less Oncology Times. 42(18):40, September 20, 2020. Favorite PDF Permissions Free
Year In Review: 2020 Mesothelioma Treatments & Clinical Trials Less Oncology Times. 42(18):25, September 20, 2020. Favorite PDF Permissions Free
Precision Therapy in Lung Cancer Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(18):21, September 20, 2020. Favorite PDF Permissions Free
Precision Therapy in Lung Cancer Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(18):21, September 20, 2020. Favorite PDF Permissions Free
Lurbinectedin (Zepzelca™) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 42(18):18, September 20, 2020. Favorite PDF Permissions Free
